Meta AnalysisID 5927
生脉制剂联合西药常规治疗冠心病的有效性与安全性：系统评价与Meta分析
CRD42021242205
Coronary Heart Diseases(CHD) is still the number one cause of death worldwide, exceeding the sum of all tumor causes.At present, the mortality rate of CHD also accounts for thefirst cause of total death in China. The tot
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 5927
- Evidence Id
- 14485
- Core Evidence Id
- 14485
- Source Meta Analysis Id
- 5909
- Herb2 Meta Analysis Id
- HBMA005909
- Crd Id
- CRD42021242205
- Title
- A systematic review and meta-analysis for efficacy and safety of Shengmai preparation with western medicine routine treatment for Coronary Heart Diseases
- Review Question
- Coronary Heart Diseases(CHD) is still the number one cause of death worldwide, exceeding the sum of all tumor causes.At present, the mortality rate of CHD also accounts for thefirst cause of total death in China. The total cost of hospitalization for AMI was as high as 13.375 billion Yuan. The main treatment for CHD mainly includes drug therapy, percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG). However, it could result in certain side effects and poor compliance. Traditional Chinese medicine (TCM) is an important part of complementary and alternative medicine (CAM), which has been widely accepted in China and applied in practice.Shengmai preparation is composed of 3 kinds of TCM (Radix Ginseng, Radix Ophiopogonis, Fructus Schisandrae Chinensis), and used in the treatment of coronary heart disease in China with uncertain effects. However, to our knowledge, there is no systematic review of its efficacy and safety in the treatment of CHD about Antiplatelet, lowering blood lipid and protecting vascular endothelial function.
- Study Type Included
- Randomized Controlled Trials
- Condition Being Studied
- Coronary Heart Disease (CHD) a serious cardiovascular disease of myocardial ischemia or necrosis caused by stenosis or occlusion by coronary atherosclerosis, which can be divided into chronic coronary artery diseases and acute coronary syndromes. CHD is still the number one cause of death worldwide, exceeding the sum of all tumor causes.At present, the mortality rate of CHD also accounts for thefirst cause of total death in China. At present, 11396, 000 people in China suffer from CHD. The mortality rate of urban/rural residents reaches 115.32 per 100, 000 and 122.04 per 100, 000, respectively, and it shows an increasing trend year by year. Every year, nearly 910, 000 patients receive percutaneous coronary intervention therapy.CHD seriously affects peoples quality of life and puts a huge economic burden on society.The total cost of hospitalization for AMI was as high as 13.375 billion Yuan.
- Participant
- Patients with a definite diagnosis of CHD were included, including chronic coronary diseases such as stable angina pectoris, ischemic cardiomyopathy, and occult CHD, and acute coronary syndrome such as unstable angina pectoris, non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction and patients after emergency PCI.Can be combined with hyperlipidemia, hypertension, diabetes and other common coronary heart disease risk factors.The subjects ranged from 18 to 80 years of age and had no gender, race or language requirements.
- Animal
- Human Disease Modelled
- Intervention
- On the basis of conventional western medicine treatment, the experimental group received Shengmai preparation (Chinese medicine preparation composed of Radix Ginseng, Radix Ophiopogonis, Fructus Schisandrae Chinensis) : Chinese patent medicine contain Shengmai injection, Yiqi Fumai injection, Shengmai capsule and Shengmai granule;Oral decoction includes Shengmai San.Each intervention was used for at least a week.The addition and subtraction of Shengmai preparation in the experimental group were excluded, including Jiawei Shengmai powder, Yixinshu capsule, Dengzhan Shengmai capsule, Shenmai injection, Shengmai preparation combined with other Chinese medicine intervention, etc
- Comparator Control
- The control group received conventional treatment for CHD, including antiplatelet, lipid-lowering and plaque stabilization, coronary artery dilation or PCI intervention. The blank control and other traditional Chinese medicine preparations were used as the control were excluded
- Main Outcome
- The primary outcomes will be major adverse cardiovascular events (MACE), including nonfatal myocardial infarction, nonfatal cardiogenic shock, coronary revascularization, coronary heart disease death, severe arrhythmias, and the frequency and duration of angina attacks. Measures of effect Measures of treatment effect.Analysis will be based on available data of included studies, the relative data (RR) or odds ratio (OR) with 95% confidence interval (CI) will be used to analyze dichotomous data. While the standardized mean difference (SMD) or weighted mean difference (WMD) with 95% CI will be used for continuous data.
- Outcome Measure
- Additional Outcome
- The secondary outcomes will be Hemorheology (whole blood viscosity, plasma viscosity, hematocrit, specific volume, fibrinogen);Platelet related indexes (platelet aggregation rate, platelet response index, platelet adhesion rate);Endothelial cell function (endothelin ET, NO, endothelial cell growth factor VEGF) lipid related indexes (LDL-C, TC, TG, HDL-C);Plasma inflammatory cytokines (TNF-α, hs-CRP, IL-6); Measures of effect Measures of treatment effect.Analysis will be based on available data of included studies, the relative data (RR) or odds ratio (OR) with 95% confidence interval (CI) will be used to analyze dichotomous data. While the standardized mean difference (SMD) or weighted mean difference (WMD) with 95% CI will be used for continuous data.
- Study Method
- Systematic review
- Keyword
- Coronary Disease; Drug Combinations; Drugs, Chinese Herbal; Humans; Phytotherapy; fructus schizandrae, radix ginseng, radix ophiopogonis drug combination
- Contact
- Organisational Affiliation
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Review Stage
- First Submission Date
- Registration Date
- Anticipated Start Date
- Anticipated Completion Date
- Title Cn
- 生脉制剂联合西药常规治疗冠心病的有效性与安全性：系统评价与Meta分析
- Title En
- A systematic review and meta-analysis for efficacy and safety of Shengmai preparation with western medicine routine treatment for Coronary Heart Diseases
- Bilingual Status
- complete